The largest database of trusted experimental protocols

D0125000

Manufactured by Merck Group
Sourced in France

D0125000 is a laboratory equipment product manufactured by Merck Group. It serves as a general-purpose device for conducting various laboratory experiments and analyses. The core function of this product is to provide a controlled and standardized environment for scientific research and testing purposes. Detailed technical specifications and intended use cases are not available for this specific product.

Automatically generated - may contain errors

2 protocols using d0125000

1

Heat-Induced Clones Generation and Drug Sensitivity

Check if the same lab product or an alternative is used in the 5 most similar protocols
To generate heat-induced clones, cells were first incubated at 42°C for 4 h over three consecutive days and then single-cell sorted (FACSAria II; BD Biosciences) based on cell size into individual wells in 96-well plates with 50% conditioned media. After ∼2–3 wk of incubation, colonies were harvested and their ploidy was analyzed by FACS and metaphase spreads. For each drug treatment, two biological replicates with two technical replicates per clone was conducted. Four hundred cells/well were plated a day before they were subjected to the indicated drug treatments for 3 h. After 1 wk of incubation under standard conditions, cells were ethanol-fixed and stained using 0.05% crystal violet (C3886; Sigma-Aldrich). Counting was performed manually. Drugs: bleomycin (ab142977; Abcam), cisplatin (ab141398; Abcam), daunorubicin (D0125000; Sigma-­Aldrich), doxorubicin (D1515; Sigma-Aldrich), oxaliplatin (ab141054; Abcam), STLC (164739; Sigma-Aldrich), paclitaxel (T7402; Sigma-Aldrich), vinblastine (V1277; Sigma-Aldrich). All drugs were dissolved in dimethyl sulfoxide (DMSO) (D2650; Sigma-Aldrich) except cisplatin, which was dissolved in saline.
+ Open protocol
+ Expand
2

Establishing AML Cell Line Resistance

Check if the same lab product or an alternative is used in the 5 most similar protocols
Acute Myeloid Leukemia (AML) cell lines HL-60, NB-4, MOLM13, and KG-1 were acquired from the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH. Cells were maintained and routinely subcultured in culture flasks at a cell density between 1 × 105 and 1 × 106 cells/mL. Cells were grown in a complete medium consisting of RPMI (PanBiotech, Aidenbach, Germany) supplemented with 10% Fetal Bovine Serum (FBS, PanBiotech) and 1% penicillin/streptomycin (PenStrep, PanBiotech). Cell cultures were maintained in a humidified incubator at 37 °C and a 5% CO2 atmosphere. To induce resistance, cells were exposed to increasing concentrations of Cytarabine (Ara-C, C3350000, Sigma, Strasbourg, France) and Daunorubicin (DNR, D0125000, Sigma) for 3–6 months. To obtain enough biomass to perform the assays, cells were grown to high densities, but not exceeding 1 × 106 viable cells/mL and with cell viability up to 90%. Viable cell estimation was performed by adding 1:1 cell suspension to 0.2% trypan blue (sc-216028, Santa Cruz Biotechnology, Dallas, TX, USA), and cells were counted in a Neubauer chamber.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!